The research and development of innovative drugs requires not only one-point policy support, but also the common support of the entire upstream and downstream industries, multi-directional, and various linksEssence
Writing | Wei Xinran
Research and development is closer to clinical needs?How to balance R & D innovation, cost control and patient needs to ensure the efficient and extensive consequences of innovative drugs?How to practice "value medical care" in the process of innovative drugs?In the face of various problems in the development of innovative drugs, this conference gave a full range of answers.
At 9 am on October 19th, the "Application of Value Medical" hosted by "Medical Community" in the development of the whole chain innovation pharmaceutical industry "forum was held in Yangpu District, Shanghai.This forum is based on the combination of case sharing and round table discussion, focusing on the theme of "the role of value medical concept in promoting the development of the full chain of the innovative pharmaceutical industry", and gives answers and answers and answers in various questions in the development of innovative drugs.think.The conference received extensive attention and support from experts, scholars, pharmaceutical companies, and innovative industry managers from medical and pharmaceutical -related fields.
At the beginning of the meeting, Wang Haiyin, director of the Health and Healthy Development Research Center of the Shanghai Municipal Health and Healthy Development Research Center, as the guest and host.He warmly welcomed and emphasized the common mission of participants in the process of innovation and development and medical and health undertakings.
Wang Haiyin, Director of the Health and Healthy Development Research Research Center of Shanghai Municipal Health and Healthy Development Research Center
SubsequentThe forum has entered a wonderful case sharing link.First of all, Chen Qiyu, vice president of the China Pharmaceutical Innovation Promotion Association and CEO of Fosun International, brought the theme of the theme of the "All -Chain Biomedical Development Policy: Opportunities and Challenges".Chen Qiyu, vice president of China Medical Innovation Promotion Association, Fosun International Co-CEO
Chen Qiyu said that the current opportunities and challenges of the R & D market for innovation drugs in my country. On the one hand, my countrys biomedical industry has experienced a transition from starting to high -speed growth to the adjustment period. Challenges such as downturnal performance of the capital market; on the other hand, today, including "All Chain Supporting Innovation Pharmaceutical Development Implementation Plan" and Shanghai "Several Opinions on Supporting the Innovation and Development of Full Chain of the Biomedical Industry", etc. Governments incentives and support policies are constantly emerging, and are committed to cultivating innovative pharmaceutical companies that are localized in China.Finally, Chen Qiyu reiterated the theme that "the development of innovative drugs requires not only one -point policy support, but also the support of the entire upstream and downstream industries."
Then, Liu Houjia, director of the Shanghai Biomedical Industry Promotion Center, shared the case sharing of the theme of "Development of Biomedical Full Chain",Out of Shanghais unique solution.
Liu Houjia, director of the Shanghai Biomedical Industry Promotion Center
Liu Houjia believes that the biomedical industry is used asThe endless risk, high investment, high return, and long cycle.He emphasized the advantages of Shanghais biomedical industry development in terms of policy environment, accelerated industrial energy levels, rich clinical resources, innovative and entrepreneurial talents, strong capital power, and gathering of superior enterprises, and showed Shanghais approval of innovative drugs to be listed on the market.The construction of the clinical research center, the construction of the integration of the industry and medical integration, and the cooperation between medical institutions and biomedical enterprises.In addition, Liu Houjia also put forward suggestions such as improving the diversified payment mechanism and improving the toughness of international competition to achieve the development of the entire chain of the biomedical industry and create a new future of value medical care.
Subsequently, Chen Bing, vice president of Astraikangs international business expansion cooperation and strategic investment, "How does multinational pharmaceutical companies support Chinese drug weapon innovation?The theme of Astracos exploration shared the theme, and explained the unique exploration of Astraon in the process of practicing value medical care and helping Chinese drug weapon innovation.
Chen Bing, vice president of Astraikon International Business Development Cooperation and Strategic Investment
Chen BingAccording to the introduction, Astrikan is committed to pioneering the scientific territory, focusing on differentiated and source innovation, integrating global resources to give partners to the full life cycle support to achieve value medical care and provide patients with high -quality and affordable medical services.Over the past 10 years, Astraikons turnover has increased more than 4 times in China, with a compound annual growth rate of more than 14%. It has introduced more than 40 global innovative drugs to transport drugs to more than 70 global markets.By 2030, the Astraikian plan will bring 20 breakthrough innovative drugs to achieve the field of disease treatment and bring medical innovation to patients to improve life.In addition, Chen Bing also emphasized the ambitions and mission of Astraikon, that is, "continuously developing the scientific territory, leading the field of disease treatment, and bringing medical innovation for patients to improve life."
Zhou Rui, the founder of Dingxin Gene, introduced the various experiences of Dingxin Gene in the development of innovative drugs, with "the good medicine that the people can afford -the development of Dingxin gene drugs"The Road" was shared by the theme.
Zhou Rui, the founder of Dingxin Gene
Zhou Rui emphasized the gene therapy as the thirdThe importance of the secondary drug technology revolution has shared the in -depth thinking of Dingxin gene in terms of the pricing logic, development costs, manufacturing costs and promotion costs of gene therapy products, as well as how to find patients and medical insurances to afford it, and the enterprise can be profitable.Balance point.In the end, he explained the mission and vision of Dingxin gene, that is, "keeping humans away from the pain and making life blooming wonderful", and becoming "the leader of genetic precision delivery industry."With the end of Zhou Ruis sharing, the case sharing session of this forum has also reached the end.
Cai Jiangnan, the founder and executive director of Shanghai Chuangqi Healthy Development Research Institute
CasesAfter the sharing, the round table discusses the theme of "opportunities and challenges of innovative drug transformation". Participants focus on "how to ensure the efficient transformation and extensiveness of innovative drugs" and "future value medical innovation in China in China innovation"Applications in the development of the medicine and device industry" and other issues.This round table discussion was the host of the founder and executive chairman of the Shanghai Chuangqi Health Development Research Institute.Chen Bing, vice president of strategic investment, and Zhou Rui, founder of Dingxin Gene, participated in the discussion.The meeting finally ended in professional discussions and warm applause.Review of the previous Taishan Awards
1
2
3,
4
5,
